Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy
By:
References
- Bianchi M, Roghmann F, Becker A, Sukumar S, Briganti A, Menon M, et al. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. <em>Can Urol Assoc J</em> 2014; <bold>8</bold>: E148-58. <pub-id pub-id-type="doi"><a href="https://doi.org/10.5489/cuaj.787" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5489/cuaj.787</a></pub-id>
- Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. <em>Int J Radiat Oncol Biol Phys</em> 2011; <bold>79</bold>: 965-76. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijrobp.2010.11.026" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2010.11.026</a></pub-id>
- Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. <em>Spine (Phila Pa 1976)</em> 1997; <bold>22</bold>: 239-45.
- Foerster R, Habermehl D, Bruckner T, Bostel T, Schlampp I, Welzel T, et al. Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. <em>Radiat Oncol</em> 2014; <bold>9</bold>: 194. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/1748-717X-9-194" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/1748-717X-9-194</a></pub-id>
- Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, et al. The stability of osseous metastases of the spine in lung cancer - a retrospective analysis of 338 cases. <em>Radiat Oncol</em> 2013; <bold>8</bold>: 200. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/1748-717X-8-200" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/1748-717X-8-200</a></pub-id>
- Schlampp I, Rieken S, Habermehl D, Bruckner T, Förster R, Debus J, et al. Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. <em>Strahlenther Onkol</em> 2014; <bold>190</bold>: 792-7. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1007/s00066-014-0651-z" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00066-014-0651-z</a></pub-id>
- Foerster R, Eisele C, Bruckner T, Bostel T, Schlampp I, Wolf R, et al. Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis. <em>Radiat Oncol</em> 2015; <bold>10</bold>: 62. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/s13014-015-0368-x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s13014-015-0368-x</a></pub-id>
- Rief H, Petersen LC, Omlor G, Akbar M, Bruckner T, Rieken S, et al. The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - a randomized trial. <em>Radiother Oncol</em> 2014; <bold>112</bold>: 133-9. <pub-id pub-id-type="doi">0.1016/j.radonc.2014.06.008</pub-id>
- Bostel T, Förster R, Schlampp I, Wolf R, Serras AF, Mayer A, et al. Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy. <em>Tumori</em> 2016; <bold>102</bold>: 156-61. <pub-id pub-id-type="doi"><a href="https://doi.org/10.5301/tj.5000382" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5301/tj.5000382</a></pub-id>
- Schlampp I, Lang H, Förster R, Wolf R, Bostel T, Bruckner T, et al. Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy. <em>Tumori</em> 2015; <bold>101</bold>: 614-20. <pub-id pub-id-type="doi"><a href="https://doi.org/10.5301/tj.5000370" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5301/tj.5000370</a></pub-id>
- Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. <em>Eur Urol</em> 2007; <bold>52</bold>: 1106-13. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.eururo.2007.02.052" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.eururo.2007.02.052</a></pub-id>
- Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. <em>Cancer</em> 2002; <bold>95</bold>: 751-7. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1002/cncr.10762" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.10762</a></pub-id>
- Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. <em>J Clin Oncol</em> 1997; <bold>15</bold>: 2564-9. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1200/jco.1997.15.7.2564" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/jco.1997.15.7.2564</a></pub-id>
- Habermehl D, Haase K, Rieken S, Debus J, Combs SE. Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy. <em>Tumori</em> 2011; <bold>97</bold>: 609-13. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1700/989.10720" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1700/989.10720</a></pub-id>
- Rief H, Heinhold M, Bruckner T, Schlampp I, Forster R, Welzel T, et al. Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy--a prospective trial. <em>Radiat Oncol</em> 2014; <bold>9</bold>: 133. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/1748-717X-9-133" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/1748-717X-9-133</a></pub-id>
- Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam H, et al. Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. <em>Radiother Oncol</em> 2017; <bold>122</bold>: 323-31. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.radonc.2016.12.031" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.radonc.2016.12.031</a></pub-id>
- Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. <em>Int J Clin Oncol</em> 2010; <bold>15</bold>: 382-9. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1007/s10147-010-0074-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10147-010-0074-5</a></pub-id>
Language: English
Page range: 189 - 194
Submitted on: Jun 9, 2017
Accepted on: Aug 14, 2017
Published on: Sep 14, 2017
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2017 Robert Foerster, Katharina Hees, Thomas Bruckner, Tilman Bostel, Ingmar Schlampp, Tanja Sprave, Nils H. Nicolay, Juergen Debus, Harald Rief, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.